证券日报网讯华大基因（300676）8月26日发布公告，在公司回答调研者提问时表示，在海外业务战略 合作方面，今年3月12日，华大基因沙特合资公司Genalive中标了折合9.5亿元人民币的沙特外送检测服 务集中采购项目订单。此次订单是沙特国家医疗集采公司NationalUnifiedProcurementCompany(以下简称 NUPCO)迄今为止采购金额规模最大、检测项目最多的外送检测标。Genalive将在全基因组测序 (WGS)、全外显子组测序(WES)、单病种Panel、无创产前基因检测(NIPT)、遗传性肿瘤筛查、胚胎植入 前遗传学检测(PGT)等方面提供服务。同时，报告期内公司持续深化与泰国公共卫生部的合作，共同推 动无创产前检测(NIPT)纳入政府医保报销范畴，并联合提供医保报销的遗传性乳腺癌卵巢癌筛查服务； 携手多家医院共建基因检测实验室，成功实现公司精准医学综合解决方案的院内落地。与此同时，在泰 国、印度尼西亚、越南等国家，公司通过参与政府项目、拓展商业合作、深化科研协作等多元化模式， 全面助力当地地中海贫血筛查工作的推进，助力提升区域内遗传病防控整体水平。公司还与阿联酋、沙 特、印度、 ...

Core Viewpoint - The precision medicine industry is undergoing a significant transformation, and BGI Genomics (300676) has released its 2024 financial report indicating "revenue pressure, strategic accumulation," which provides insights into the industry's transition logic [1] Group 1: Business Strategy and Growth - BGI Genomics is restructuring its growth core through a combination of "technological breakthroughs, scenario expansion, and data solutions," transitioning from a "single-driven reproductive screening" model to a "full lifecycle precision medical service platform" [1] - The company has established itself as a leader in non-invasive prenatal testing (NIPT) with international standards in sensitivity and specificity, launching new testing reagents for chromosomal abnormalities and developing long-read sequencing products for thalassemia detection [2][3] - The company has served over 34.58 million individuals in reproductive health testing, creating a vast sample library that supports technological iteration and provides valuable resources for rare disease research [2] Group 2: Performance and Revenue Growth - Despite slight fluctuations in overall revenue from reproductive health, significant growth has been observed in specific segments, with newborn genetic disease screening revenue increasing by approximately 47.38% year-on-year and hereditary disease testing series revenue growing by about 53.13% [3] - The cancer prevention and infection detection sectors have also shown remarkable results, with cancer-related revenue increasing by 19.02% year-on-year, and colorectal cancer detection revenue surging by 270.60% [5][6] Group 3: Technological Advancements and Market Expansion - BGI Genomics has developed a comprehensive solution for infectious disease detection, covering various patient demographics and offering high-throughput microbial gene detection products [6] - The company is transitioning towards "intelligent services" by leveraging AI technology to enhance data value, launching the "13311i" disease prevention system that integrates multiple testing modalities [7][8] - The establishment of the i99 division and the launch of the Ai99 total inspection system signify the company's commitment to creating a health management ecosystem that emphasizes disease prevention [8] Group 4: Future Outlook - Although BGI Genomics faces short-term revenue and profit pressures in 2024, its strategic positioning in technology reserves, market collaboration, and transformation efforts are showing results [9] - The company's innovations in the NIPT field, rapid growth in cancer early screening products, and expansion into international markets highlight its potential for collaborative business development [9] - The shift towards "intelligent services" and the integration of AI and multi-omics data are expected to support long-term growth, with increasing clinical demands and health management awareness further enhancing the company's innovative leadership [9]